UK clinical trials fall as Brexit clouds drug approval process

FILE PHOTO: An aircract flies over The European Medecines Agency and Ernst and Young's building in Canary Wharf on a clear morning in London, Britain, August 8, 2018. REUTERS/Hannah McKay/File Photo

LONDON (Reuters) – The number of new clinical trials started in Britain last year was 25 percent lower than the average for 2009-16, as anxiety about Brexit’s impact on future medicines regulation made companies hesitate about running studies in the country. A total of 597 trials were initiated in Britain in 2017, against an average […]

Continue reading this article with a Fiji Times online membership.

More Stories